In KRAS-mutated colorectal tumors, simvastatin can inhibit KRAS prenylation and activate endoplasmic reticulum stress, thereby increasing tumor immunogenicity. When combined with chemotherapeutic agents such as oxaliplatin, they significantly boost antitumor immune responses. This evidence concerns the gene KRAS and colorectal neoplasm.